{
  "trial_id": "NCT00781885",
  "trial_group": "hypertension",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, type of PAH (idiopathic, familial, associated with collagen vascular disease, induced by anorexigens), clinical stability, previous cardiac catheterization results (PAPm, PCWP, PVR), current PAH medication (ERA, PDE-5, combination), six-minute walk distance (6MWD), ability to communicate effectively, reliability and compliance with study protocol, informed consent status, childbearing potential and method of birth control (if applicable).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Body Mass Index",
        "Respiratory Rate",
        "Temperature",
        "Systolic Blood Pressure (SBP)",
        "Diastolic Blood Pressure (DBP)",
        "Weight",
        "Electrocardiogram (ECG) Intervals"
      ],
      "remaining_candidate_features": [
        "type of PAH (idiopathic, familial, associated with collagen vascular disease, induced by anorexigens)",
        "clinical stability",
        "previous cardiac catheterization results (PAPm, PCWP, PVR)",
        "current PAH medication (ERA, PDE-5, combination)",
        "six-minute walk distance (6MWD)",
        "ability to communicate effectively",
        "reliability and compliance with study protocol",
        "informed consent status",
        "childbearing potential and method of birth control (if applicable)"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Type of PAH (idiopathic, familial, associated with collagen vascular disease, induced by anorexigens), Baseline Pulmonary Arterial Pressure (PAPm), Baseline Pulmonary Capillary Wedge Pressure (PCWP), Baseline Pulmonary Vascular Resistance (PVR), Six-minute walk distance (6MWD), Current use of endothelin receptor antagonist (ERA) or phosphodiesterase inhibitor (PDE-5),",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Body Mass Index",
        "Respiratory Rate",
        "Temperature",
        "Systolic Blood Pressure (SBP)",
        "Diastolic Blood Pressure (DBP)",
        "Weight",
        "Electrocardiogram (ECG) Intervals"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Type of PAH (idiopathic, familial, associated with collagen vascular disease, induced by anorexigens)",
        "Baseline Pulmonary Arterial Pressure (PAPm)",
        "Baseline Pulmonary Capillary Wedge Pressure (PCWP)",
        "Baseline Pulmonary Vascular Resistance (PVR)",
        "Six-minute walk distance (6MWD)",
        "Current use of endothelin receptor antagonist (ERA) or phosphodiesterase inhibitor (PDE-5)"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Six-minute walk distance, Pulmonary artery pressure, Pulmonary capillary wedge pressure, Pulmonary vascular resistance, World Health Organization functional class, Prior PAH therapy, Duration of PAH diagnosis.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Body Mass Index",
          "Body Mass Index"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Respiratory Rate",
        "Temperature",
        "Systolic Blood Pressure (SBP)",
        "Diastolic Blood Pressure (DBP)",
        "Weight",
        "Electrocardiogram (ECG) Intervals"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Six-minute walk distance",
        "Pulmonary artery pressure",
        "Pulmonary capillary wedge pressure",
        "Pulmonary vascular resistance",
        "World Health Organization functional class",
        "Prior PAH therapy",
        "Duration of PAH diagnosis"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), six-minute walk distance (6MWD), pulmonary artery pressure (PAPm), pulmonary capillary wedge pressure (PCWP), pulmonary vascular resistance (PVR), use of endothelin receptor antagonist (ERA) or phosphodiesterase inhibitor (PDE-5), duration of PAH diagnosis, duration of PAH treatment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Body Mass Index",
          "body mass index (BMI)"
        ],
        [
          "Weight",
          "weight"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Respiratory Rate",
        "Temperature",
        "Systolic Blood Pressure (SBP)",
        "Diastolic Blood Pressure (DBP)",
        "Electrocardiogram (ECG) Intervals"
      ],
      "remaining_candidate_features": [
        "height",
        "six-minute walk distance (6MWD)",
        "pulmonary artery pressure (PAPm)",
        "pulmonary capillary wedge pressure (PCWP)",
        "pulmonary vascular resistance (PVR)",
        "use of endothelin receptor antagonist (ERA) or phosphodiesterase inhibitor (PDE-5)",
        "duration of PAH diagnosis",
        "duration of PAH treatment."
      ]
    }
  }
}